 |
 |
|
Lancashire and South Cumbria
Formulary |
| Formulary Chapter 8: Malignant disease and immunosuppression - Full Section
|
| Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
|
|
08.01 |
Cytotoxic drugs (0,0)
|
|
|
Side-effects of cytotoxic drugs (0,0)
|
|
|
Drugs for cytotoxic-induced side-effects (0,0)
|
|
08.01.01 |
Alkylating drugs (0,0)
|
|
08.01.02 |
Anthracyclines and other cytotoxic antibiotics
(2,0)
|
|
08.01.03 |
Antimetabolites
(4,0)
|
|
08.01.04 |
Vinca alkaloids and etoposide (0,0)
|
|
08.01.05 |
Other antineoplastic drugs (0,0)
|
|
|
Amsacrine (0,0)
|
|
|
Arsenic trioxide (0,0)
|
|
|
Bevacizumab (0,0)
|
|
|
Bexarotene (0,0)
|
|
|
Bortezomib (0,0)
|
|
|
Brentuximab vedotin (0,0)
|
|
|
Cetuximab (0,0)
|
|
|
Crisantaspase (0,0)
|
|
|
Dacarbazine and Temozolomide (0,0)
|
|
|
Erlotinib (0,0)
|
|
|
Hydroxycarbamide (0,0)
|
|
|
Imatinab (0,0)
|
|
|
Ipilimumab (0,0)
|
|
|
Mitotane (0,0)
|
|
|
Panitumumab (0,0)
|
|
|
Pentostatin (0,0)
|
|
|
Platinum compounds (0,0)
|
|
|
Porfimer sodium and temoporfin (0,0)
|
|
|
Procarbazine (0,0)
|
|
|
Protein kinase inhibitors (0,0)
|
|
|
Taxanes (0,0)
|
|
|
Topoisomerase I inhibitors (0,0)
|
|
|
Trabectedin (0,0)
|
|
|
Trastuzumab (0,0)
|
|
|
Tretinoin (0,0)
|
|
|
Vismodegib (0,0)
|
|
08.02 |
Drugs affecting the immune response
(1,0)
|
|
|
Immunosuppressant therapy
(2,0)
|
|
08.02.01 |
Antiproliferative immunosuppressants
(2,0)
|
|
08.02.02 |
Corticosteroids and other immunosuppressants
(7,0)
|
|
08.02.03 |
Anti-lymphocyte monoclonal antibodies
(5,0)
|
|
08.02.04 |
Other immunomodulating drugs
(5,0)
|
|
|
Interferon Alfa
(2,0)
|
|
|
Interferon beta
(3,0)
|
|
|
Interferon gamma (0,0)
|
|
|
Aldesleukin (0,0)
|
|
|
BCG bladder instillation
(1,0)
|
|
|
Canakinumab (0,0)
|
|
|
Dimethyl fumarate (0,0)
|
|
|
Fingolimod (0,0)
|
|
|
Glatiramer acetate
(1,0)
|
|
|
Histamine (0,0)
|
|
|
Lenalidomide, pomalidomide, and thalidomide (0,0)
|
|
|
Mifamurtide (0,0)
|
|
|
Natalizumab
(1,0)
|
|
|
Teriflunomide (0,0)
|
|
08.03 |
Sex hormones and hormone antagonists in malignant disease (0,0)
|
|
08.03.01 |
Oestrogens
(2,0)
|
|
08.03.02 |
Progestogens
(3,0)
|
|
08.03.03 |
Androgens (0,0)
|
|
08.03.04 |
Hormone antagonists (0,0)
|
|
08.03.04.01 |
Breast cancer
(5,0)
|
|
08.03.04.02 |
Prostate cancer and gonadorelin analogues (0,0)
|
|
|
Gonadorelin analogues
(1,0)
|
|
|
Anti-androgens
(7,0)
|
|
08.03.04.03 |
Somatostatin analogues
(3,0)
|
|
|
|
